{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:48:19Z","timestamp":1792316899327,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["1002720595"],"award-info":[{"award-number":["1002720595"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["1002720595"],"award-info":[{"award-number":["1002720595"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["1002720595"],"award-info":[{"award-number":["1002720595"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["1002720595"],"award-info":[{"award-number":["1002720595"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"DOD | Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["1002720595"],"award-info":[{"award-number":["1002720595"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006234","name":"DOE | LDRD | Sandia National Laboratories","doi-asserted-by":"publisher","award":["190245"],"award-info":[{"award-number":["190245"]}],"id":[{"id":"10.13039\/100006234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venezuelan equine encephalitis virus (VEEV) poses a major public health risk due to its amenability for use as a bioterrorism agent and its severe health consequences in humans. ML336 is a recently developed chemical inhibitor of VEEV, shown to effectively reduce VEEV infection <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. However, its limited solubility and stability could hinder its clinical translation. To overcome these limitations, lipid-coated mesoporous silica nanoparticles (LC-MSNs) were employed. The large surface area of the MSN core promotes hydrophobic drug loading while the liposome coating retains the drug and enables enhanced circulation time and biocompatibility, providing an ideal ML336 delivery platform. LC-MSNs loaded 20\u2009\u00b1\u20093.4\u2009\u03bcg ML336\/mg LC-MSN and released 6.6\u2009\u00b1\u20091.3\u2009\u03bcg\/mg ML336 over 24 hours. ML336-loaded LC-MSNs significantly inhibited VEEV <jats:italic>in vitro<\/jats:italic> in a dose-dependent manner as compared to unloaded LC-MSNs controls. Moreover, cell-based studies suggested that additional release of ML336 occurs after endocytosis. <jats:italic>In vivo<\/jats:italic> safety studies were conducted in mice, and LC-MSNs were not toxic when dosed at 0.11\u2009g LC-MSNs\/kg\/day for four days. ML336-loaded LC-MSNs showed significant reduction of brain viral titer in VEEV infected mice compared to PBS controls. Overall, these results highlight the utility of LC-MSNs as drug delivery vehicles to treat VEEV.<\/jats:p>","DOI":"10.1038\/s41598-018-32033-w","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T13:48:26Z","timestamp":1536760106000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Lipid-Coated Mesoporous Silica Nanoparticles for the Delivery of the ML336 Antiviral to Inhibit Encephalitic Alphavirus Infection"],"prefix":"10.1038","volume":"8","author":[{"given":"Annette E.","family":"LaBauve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torri E.","family":"Rinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"Noureddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita E.","family":"Serda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Y.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Jeffery","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl Y.","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Negrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"32033_CR1","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1128\/JVI.02330-07","volume":"82","author":"S Atasheva","year":"2008","unstructured":"Atasheva, S., Garmashova, N., Frolov, I. & Frolova, E. Venezuelan equine encephalitis virus capsid protein inhibits nuclear import in Mammalian but not in mosquito cells. J Virol 82, 4028\u20134041, https:\/\/doi.org\/10.1128\/JVI.02330-07 (2008).","journal-title":"J Virol"},{"key":"32033_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2217\/fvl.13.42","volume":"8","author":"LP Nagata","year":"2013","unstructured":"Nagata, L. P. & Wong, J. P. Hu, W.-g. & Wu, J. Q. Vaccines and therapeutics for the encephalitic alphaviruses. Future Virology 8, 661\u2013674 (2013).","journal-title":"Future Virology"},{"key":"32033_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0166-3542(02)00203-6","volume":"57","author":"RW Sidwell","year":"2003","unstructured":"Sidwell, R. W. & Smee, D. F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Research 57, 101\u2013111, https:\/\/doi.org\/10.1016\/s0166-3542(02)00203-6 (2003).","journal-title":"Antiviral Research"},{"key":"32033_CR4","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1021\/jm501203v","volume":"57","author":"CE Schroeder","year":"2014","unstructured":"Schroeder, C. E. et al. Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus. J Med Chem 57, 8608\u20138621, https:\/\/doi.org\/10.1021\/jm501203v (2014).","journal-title":"J Med Chem"},{"key":"32033_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","volume":"140","author":"MA Zacks","year":"2010","unstructured":"Zacks, M. A. & Paessler, S. Encephalitic alphaviruses. Vet Microbiol 140, 281\u2013286, https:\/\/doi.org\/10.1016\/j.vetmic.2009.08.023 (2010).","journal-title":"Vet Microbiol"},{"key":"32033_CR6","doi-asserted-by":"publisher","first-page":"e1004213","DOI":"10.1371\/journal.ppat.1004213","volume":"10","author":"DH Chung","year":"2014","unstructured":"Chung, D. H. et al. Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2. PLoS Pathog 10, e1004213, https:\/\/doi.org\/10.1371\/journal.ppat.1004213 (2014).","journal-title":"PLoS Pathog"},{"key":"32033_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.antiviral.2008.07.002","volume":"80","author":"JG Julander","year":"2008","unstructured":"Julander, J. G. et al. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 80, 309\u2013315, https:\/\/doi.org\/10.1016\/j.antiviral.2008.07.002 (2008).","journal-title":"Antiviral Res"},{"key":"32033_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.antiviral.2008.01.007","volume":"78","author":"JG Julander","year":"2008","unstructured":"Julander, J. G. et al. C3H\/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res 78, 230\u2013241 (2008).","journal-title":"Antiviral Res"},{"key":"32033_CR9","doi-asserted-by":"publisher","first-page":"e34761","DOI":"10.1371\/journal.pone.0034761","volume":"7","author":"K Kehn-Hall","year":"2012","unstructured":"Kehn-Hall, K. et al. Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection. PLoS One 7, e34761, https:\/\/doi.org\/10.1371\/journal.pone.0034761 (2012).","journal-title":"PLoS One"},{"key":"32033_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.antiviral.2017.04.014","volume":"143","author":"RM Langsjoen","year":"2017","unstructured":"Langsjoen, R. M. et al. Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential. Antiviral Res 143, 246\u2013251, https:\/\/doi.org\/10.1016\/j.antiviral.2017.04.014 (2017).","journal-title":"Antiviral Res"},{"key":"32033_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.antiviral.2014.10.002","volume":"112","author":"C Madsen","year":"2014","unstructured":"Madsen, C. et al. Small molecule inhibitors of Ago2 decrease Venezuelan equine encephalitis virus replication. Antiviral Res 112, 26\u201337, https:\/\/doi.org\/10.1016\/j.antiviral.2014.10.002 (2014).","journal-title":"Antiviral Res"},{"key":"32033_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/adma.201104763","volume":"24","author":"F Tang","year":"2012","unstructured":"Tang, F., Li, L. & Chen, D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24, 1504\u20131534, https:\/\/doi.org\/10.1002\/adma.201104763 (2012).","journal-title":"Adv Mater"},{"key":"32033_CR13","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/smll.200901789","volume":"6","author":"JL Vivero-Escoto","year":"2010","unstructured":"Vivero-Escoto, J. L., Slowing, I. I., Trewyn, B. G. & Lin, V. S. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6, 1952\u20131967, https:\/\/doi.org\/10.1002\/smll.200901789 (2010).","journal-title":"Small"},{"key":"32033_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.addr.2012.07.018","volume":"65","author":"V Mamaeva","year":"2013","unstructured":"Mamaeva, V., Sahlgren, C. & Linden, M. Mesoporous silica nanoparticles in medicine\u2013recent advances. Adv Drug Deliv Rev 65, 689\u2013702, https:\/\/doi.org\/10.1016\/j.addr.2012.07.018 (2013).","journal-title":"Adv Drug Deliv Rev"},{"key":"32033_CR15","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","volume":"60","author":"II Slowing","year":"2008","unstructured":"Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W. & Lin, V. S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60, 1278\u20131288, https:\/\/doi.org\/10.1016\/j.addr.2008.03.012 (2008).","journal-title":"Adv Drug Deliv Rev"},{"key":"32033_CR16","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1039\/c1cs15246g","volume":"41","author":"Z Li","year":"2012","unstructured":"Li, Z., Barnes, J. C., Bosoy, A., Stoddart, J. F. & Zink, J. I. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 41, 2590\u20132605, https:\/\/doi.org\/10.1039\/c1cs15246g (2012).","journal-title":"Chem Soc Rev"},{"key":"32033_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/smll.200700005","volume":"3","author":"J Lu","year":"2007","unstructured":"Lu, J., Liong, M., Zink, J. I. & Tamanoi, F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341\u20131346, https:\/\/doi.org\/10.1002\/smll.200700005 (2007).","journal-title":"Small"},{"key":"32033_CR18","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1039\/c0nr00156b","volume":"2","author":"JM Rosenholm","year":"2010","unstructured":"Rosenholm, J. M., Sahlgren, C. & Linden, M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles\u2013opportunities & challenges. Nanoscale 2, 1870\u20131883, https:\/\/doi.org\/10.1039\/c0nr00156b (2010).","journal-title":"Nanoscale"},{"key":"32033_CR19","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1021\/acsnano.6b02819","volume":"10","author":"PN Durfee","year":"2016","unstructured":"Durfee, P. N. et al. Mesoporous Silica Nanoparticle-Supported Lipid Bilayers (Protocells) for Active Targeting and Delivery to Individual Leukemia Cells. ACS Nano 10, 8325\u20138345, https:\/\/doi.org\/10.1021\/acsnano.6b02819 (2016).","journal-title":"ACS Nano"},{"key":"32033_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jneumeth.2016.09.003","volume":"273","author":"MA Gonzalez Porras","year":"2016","unstructured":"Gonzalez Porras, M. A. et al. A novel approach for targeted delivery to motoneurons using cholera toxin-B modified protocells. J Neurosci Methods 273, 160\u2013174, https:\/\/doi.org\/10.1016\/j.jneumeth.2016.09.003 (2016).","journal-title":"J Neurosci Methods"},{"key":"32033_CR21","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1021\/nl100991w","volume":"10","author":"V Cauda","year":"2010","unstructured":"Cauda, V. et al. Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett 10, 2484\u20132492, https:\/\/doi.org\/10.1021\/nl100991w (2010).","journal-title":"Nano Lett"},{"key":"32033_CR22","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/smll.201502119","volume":"12","author":"KS Butler","year":"2016","unstructured":"Butler, K. S. et al. Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery. Small 12, 2173\u20132185, https:\/\/doi.org\/10.1002\/smll.201502119 (2016).","journal-title":"Small"},{"key":"32033_CR23","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.1021\/nn402062f","volume":"7","author":"LM Bimbo","year":"2013","unstructured":"Bimbo, L. M. et al. Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles. ACS Nano 7, 6884\u20136893, https:\/\/doi.org\/10.1021\/nn402062f (2013).","journal-title":"ACS Nano"},{"key":"32033_CR24","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1021\/nl801596a","volume":"8","author":"MM van Schooneveld","year":"2008","unstructured":"van Schooneveld, M. M. et al. Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation. Nano Letters 8, 2517\u20132525, https:\/\/doi.org\/10.1021\/nl801596a (2008).","journal-title":"Nano Letters"},{"key":"32033_CR25","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1021\/mp200613y","volume":"9","author":"RA Roggers","year":"2012","unstructured":"Roggers, R. A., Lin, V. S. & Trewyn, B. G. Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization. Mol Pharm 9, 2770\u20132777, https:\/\/doi.org\/10.1021\/mp200613y (2012).","journal-title":"Mol Pharm"},{"key":"32033_CR26","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1016\/j.biomaterials.2013.06.001","volume":"34","author":"IT Teng","year":"2013","unstructured":"Teng, I. T. et al. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer. Biomaterials 34, 7462\u20137470, https:\/\/doi.org\/10.1016\/j.biomaterials.2013.06.001 (2013).","journal-title":"Biomaterials"},{"key":"32033_CR27","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1021\/nn901376h","volume":"4","author":"L-S Wang","year":"2010","unstructured":"Wang, L.-S. et al. Biofunctionalized Phospholipid-Capped Mesoporous Silica Nanoshuttles for Targeted Drug Delivery: Improved Water Suspensibility and Decreased Nonspecific Protein Binding. ACS Nano 4, 4371\u20134379, https:\/\/doi.org\/10.1021\/nn901376h (2010).","journal-title":"ACS Nano"},{"key":"32033_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1021\/ar3000986","volume":"46","author":"D Tarn","year":"2013","unstructured":"Tarn, D. et al. Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility. Accounts of Chemical Research 46, 792\u2013801, https:\/\/doi.org\/10.1021\/ar3000986 (2013).","journal-title":"Accounts of Chemical Research"},{"key":"32033_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/nl048153y","volume":"5","author":"S Mornet","year":"2005","unstructured":"Mornet, S., Lambert, O., Duguet, E. & Brisson, A. The Formation of Supported Lipid Bilayers on Silica Nanoparticles Revealed by Cryoelectron Microscopy. Nano Letters 5, 281\u2013285, https:\/\/doi.org\/10.1021\/nl048153y (2005).","journal-title":"Nano Letters"},{"key":"32033_CR30","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1021\/ja808018y","volume":"131","author":"J Liu","year":"2009","unstructured":"Liu, J., Stace-Naughton, A., Jiang, X. & Brinker, C. J. Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles. Journal of the American Chemical Society 131, 1354\u20131355, https:\/\/doi.org\/10.1021\/ja808018y (2009).","journal-title":"Journal of the American Chemical Society"},{"key":"32033_CR31","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1021\/am5082793","volume":"7","author":"N Han","year":"2015","unstructured":"Han, N. et al. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance. ACS Appl Mater Interfaces 7, 3342\u20133351, https:\/\/doi.org\/10.1021\/am5082793 (2015).","journal-title":"ACS Appl Mater Interfaces"},{"key":"32033_CR32","doi-asserted-by":"publisher","first-page":"7662","DOI":"10.1016\/j.biomaterials.2013.06.042","volume":"34","author":"D Wang","year":"2013","unstructured":"Wang, D. et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 34, 7662\u20137673, https:\/\/doi.org\/10.1016\/j.biomaterials.2013.06.042 (2013).","journal-title":"Biomaterials"},{"key":"32033_CR33","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.biomaterials.2014.01.013","volume":"35","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Biomaterials 35, 3650\u20133665, https:\/\/doi.org\/10.1016\/j.biomaterials.2014.01.013 (2014).","journal-title":"Biomaterials"},{"key":"32033_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejps.2016.06.001","volume":"95","author":"E von Haartman","year":"2016","unstructured":"von Haartman, E., Lindberg, D., Prabhakar, N. & Rosenholm, J. M. On the intracellular release mechanism of hydrophobic cargo and its relation to the biodegradation behavior of mesoporous silica nanocarriers. Eur J Pharm Sci 95, 17\u201327, https:\/\/doi.org\/10.1016\/j.ejps.2016.06.001 (2016).","journal-title":"Eur J Pharm Sci"},{"key":"32033_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10971-016-4053-9","volume":"79","author":"K Braun","year":"2016","unstructured":"Braun, K. et al. Dissolution kinetics of mesoporous silica nanoparticles in different simulated body fluids. Journal of Sol-Gel Science and Technology 79, 319\u2013327, https:\/\/doi.org\/10.1007\/s10971-016-4053-9 (2016).","journal-title":"Journal of Sol-Gel Science and Technology"},{"key":"32033_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jconrel.2017.07.047","volume":"262","author":"A Maleki","year":"2017","unstructured":"Maleki, A. et al. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs. J Control Release 262, 329\u2013347, https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.047 (2017).","journal-title":"J Control Release"},{"key":"32033_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6633","volume":"5","author":"DH Han","year":"2014","unstructured":"Han, D. H. et al. Direct cellular delivery of human proteasomes to delay tau aggregation. Nat Commun 5, 5633, https:\/\/doi.org\/10.1038\/ncomms6633 (2014).","journal-title":"Nat Commun"},{"key":"32033_CR38","doi-asserted-by":"publisher","first-page":"12954","DOI":"10.1128\/JVI.02242-12","volume":"86","author":"B Harmon","year":"2012","unstructured":"Harmon, B.\u00a0et al.\u00a0Rift Valley Fever Virus Strain MP-12 Enters Mammalian Host Cells via Caveola-Mediated Endocytosis.\u00a0J Virol\u00a086,\u00a012954\u201312970, https:\/\/doi.org\/10.1128\/JVI.02242-12\u00a0(2012).\u00a0","journal-title":"J Virol"},{"key":"32033_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biomaterials.2015.02.014","volume":"52","author":"J Riikonen","year":"2015","unstructured":"Riikonen, J. et al. Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib. Biomaterials 52, 44\u201355, https:\/\/doi.org\/10.1016\/j.biomaterials.2015.02.014 (2015).","journal-title":"Biomaterials"},{"key":"32033_CR40","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/smll.201000538","volume":"6","author":"J Lu","year":"2010","unstructured":"Lu, J., Liong, M., Li, Z., Zink, J. I. & Tamanoi, F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6, 1794\u20131805, https:\/\/doi.org\/10.1002\/smll.201000538 (2010).","journal-title":"Small"},{"key":"32033_CR41","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1021\/ja4082414","volume":"135","author":"JL Townson","year":"2013","unstructured":"Townson, J. L. et al. Re-examining the size\/charge paradigm: differing in vivo characteristics of size- and charge-matched mesoporous silica nanoparticles. J Am Chem Soc 135, 16030\u201316033, https:\/\/doi.org\/10.1021\/ja4082414 (2013).","journal-title":"J Am Chem Soc"},{"key":"32033_CR42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1039\/C0CC02923H","volume":"47","author":"YS Lin","year":"2011","unstructured":"Lin, Y. S., Abadeer, N. & Haynes, C. L. Stability of small mesoporous silica nanoparticles in biological media. Chem Commun (Camb) 47, 532\u2013534, https:\/\/doi.org\/10.1039\/c0cc02923h (2011).","journal-title":"Chem Commun (Camb)"},{"key":"32033_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01030-17","volume":"91","author":"MB Sherman","year":"2017","unstructured":"Sherman, M. B. et al. Stability of cucumber necrosis virus at the quasi-6-fold axis affects zoospore transmission. Journal of Virology 91, 1\u201312 (2017).","journal-title":"Journal of Virology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32033-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32033-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32033-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:50:20Z","timestamp":1671616220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32033-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32033"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32033-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.A.N., A.E.L., T.R. and C.J.B. are listed as inventors on a patent application (No. 62\/689,037) filed by National Technology and Engineering Solutions of Sandia, LLC and STC.UNM related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13990"}}